Spike Health Wall Breaking Technology Patented Ganoderma Lucidum Spore Powder One-time Wall Breaking Rate Over 99%
Release time:
2022-04-06
99%. Ganoderma lucidum spore cell wall is extremely strong, composed of chitin, cellulose and lignin and other substances, extremely difficult to be digested by human stomach acid. Only by opening the outer wall, the effective ingredients tightly wrapped by the outer wall can be absorbed by the human body to the greatest extent. At present, the wall breaking methods commonly used by health product manufacturers mainly include airflow, mechanical shearing and grinding, etc. The one-time wall breaking rate is mostly above
95%. If the wall is broken repeatedly, although the wall breaking rate can be further improved, the problems such as temperature rise and adhesion caused by the extension of production cycle will cause damage to the effective components of spore powder. Spore powder products with sharp peaks and health originally used mechanical shearing technology. According to the different characteristics of raw materials, the primary wall breaking rate is about 95%-98% . After using the new technology, the wall breaking rate can be stably maintained above 99% within the same production time, and the production efficiency is obviously improved. Spike Health, a new patented technology of spore powder breaking the wall, is to preliminarily destroy cellulose and lignin in the wall shell of traditional Chinese medicine by high-pressure puffing before mechanical shearing, so as to make it loose, and then treat it by pulse discharge plasma. During pulse discharge, a large amount of energy is released in an instant, forming a large pulse impact, causing the wall shell to rupture. After the wall shell is broken, the mechanical wall is broken, so as to effectively improve the rate of one-time wall breaking, avoid repeated feeding, and shorten the wall breaking time. In addition, ceramic composite particles formed by mixing and sintering nano-iron tetraoxide, porous zirconia, rod-shaped nano-alumina and other materials in the powder during the wall breaking process can not only prevent the agglomeration and agglomeration of traditional Chinese medicine due to static electricity generation, but also ensure the fluidity of traditional Chinese medicine. The composite particles can also timely export heat and static electricity, which can avoid local heating of traditional Chinese medicine to a certain extent and reduce the probability of effective substances losing activity due to heat. After adopting the new technology, not only the production efficiency is improved, the effective components of spore powder are better maintained, and the safety is higher, but also the energy consumption for temperature control in the production process is reduced.
(Lu Guosheng)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page